Ligand Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Ligand Pharmaceuticals Incorporated

04/05/2023 22:43

* Ligand Pharmaceuticals Inc  LGND.OQ  reported quarterly
adjusted
earnings of $2.28​​ per share for the quarter ended in March.
The mean expectation of five analysts for the quarter was
for earnings of 89 cents per share.
    * Revenue fell 3.8% to $43.98 million from a year ago;
analysts
expected $34.04 million. 
    * Ligand Pharmaceuticals Inc's reported EPS for the quarter
was
$2.33​.
    * The mean earnings estimate of analysts had risen by
about 92.8%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Ligand Pharmaceuticals Inc shares had risen by 2.5% this
quarter and gained 12.9% so far this year.
    * The company reported quarterly net income of $41.95
million.
    * Wall Street's median 12-month price target for Ligand
Pharmaceuticals Inc is $107.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 09:43 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      0.89           2.28           Beat
 Dec. 31 2022      1.19           1.36           Beat
 Sep. 30 2022      0.43           1.31           Beat
 Jun. 30 2022      0.43           1.03           Beat